Replicel Interview on Bald Truthhttp://www.replicel.com/replicel-life-sciences-president-and-ceo-david-hall-interviewed-on-the-bald-truth/?utm_source=rss&utm_medium=rss&utm_campaign=replicel-life-sciences-president-and-ceo-david-hall-interviewed-on-the-bald-truth

Sorry for the double post!

Update of an e-mail that I received from RepliCel:

May 17, 2012

By RepliCel on May 17, 2012
VANCOUVER, BC - May 17, 2012 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report that further analysis of results from its successful first-in-man clinical trial revealed substantial hair growth including seven participants with growth in excess of 10%, including 17.2%, 19.2% and 19.6%. Furthermore, there were no negative health effects.

"The RepliCel TS001-2009 trial was a first-in-man trial with a primary endpoint of safety and this was confirmed emphatically," stated Dr. Rolf Hoffmann, Chief Medical Officer at RepliCel. "Even though the size of the trial was only powered for safety measures, secondary endpoints were included in interim analysis to give us an early look at efficacy to allow us to better drive the design of the next steps of the clinical development of the RepliCeltm procedure," Dr. Hoffmann concluded.

To view the full May 17th news release, please visit http://www.replicel.com/furthe...-man-clinical-trial/.

Kind Regards,

RepliCel Life Sciences

Any new news about Replicel?

-------------------------
"No one is ever defeated until defeat has been accepted as a reality."

-20.4.2011 Avodart 0.5mg
-Nizoral 2009 1-2/week
-20.2.2012 Rogaine Foam (at nights)
-RUM 15.3.2012 (temples)
-1.7.2012Fin 1mg

Any new news about Replicel?

-------------------------
"No one is ever defeated until defeat has been accepted as a reality."

-20.4.2011 Avodart 0.5mg
-Nizoral 2009 1-2/week
-20.2.2012 Rogaine Foam (at nights)
-RUM 15.3.2012 (temples)
-1.7.2012Fin 1mg

Update from Replicel:

RepliCel to Present at Rodman and Renshaw Global Investment
Conference
September 10, 2012 - Vancouver, British Columbia - RepliCel Life Sciences Inc.'s (the "Company" or
"RepliCel") (OTCBB:REPCF) today announces that David Hall, CEO and President, will be presenting at
the Rodman & Renshaw Global Investment Conference. Mr. Hall is scheduled to present on
September 11th at 2:25 PM ET in the Starlight South suite at the Waldorf Astoria hotel in New York.
The 20 minute presentation will include an update on corporate events and plans for a Phase II
dose-ranging trial using RepliCeltm as a potential treatment for hair loss in men and women.
The presentation will be webcast and posted on Rodman and Renshaw's website at
www.wsw.com/webcast/rrshq22/repcf and on RepliCel's website at www.replicel.com in the media
section.
About RepliCel Life Sciences Inc.
The Company has developed RepliCeltm, a patented natural hair cell replication technology that has
the potential to become the world's first, minimally invasive solution for androgenetic alopecia and
general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology
that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into
areas of hair loss, initiates natural hair regeneration. The Company is currently conducting
first-in-man clinical trials. Additional information on RepliCel is available at www.replicel.com.
For more information please contact:
Tammey George, Director of Communications
Telephone: 604-248-8696
tg@replicel.com
www.replicel.com

Have you rear this? http://www.replicel.com/wp-con...Ia-Interim-Results.pdf ???

*read

European trials, wonder where they'll be.

Update from Replicel:

RepliCel Completes First Pre-Filing Review with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Process

Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013

VANCOUVER, BC - November 7, 2012 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report on its pre-filing scientific meeting with the German Competent Authority responsible for cellular therapies - the Paul Ehrlich Institute (PEI).

During the latter part of 2012, the Company has been making enhancements to the RepliCeltm procedure to improve the quality, characterization, and shelf-life of its autologous hair cell product which has been named RCH-01. RepliCel's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on its proposed current Good Manufacturing Practice(cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of RepliCel's upcoming Phase II, dose-ranging clinical trial. The PEI experts agreed that the proposed manufacturing process for RCH-01 is acceptable for the conduct of a Phase II study and recommended some additional validation work on the manufacturing process be included in the investigational medicinal product dossier (IMPD) that forms part of the clinical trial application.

The results achieved at this meeting have laid the groundwork for the next pre-filing meeting with PEI experts during which time RepliCel's scientific team will discuss the design and methodology of its Phase II clinical trial to be implemented in Germany. This trial is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants. In addition to augmenting the Company's information on the safety of injections of RCH-01, the trial will also provide insight into the optimal treatment regimen for hair growth. The meeting with the PEI, and subsequent confirmation of the design of the Phase II clinical trial, will be completed prior to the end of 2012.

RepliCel's scientific team anticipates the non-binding recommendations received at these meetings, in advance of submitting the formal clinical trial application, will help ensure that all regulatory requirements are met in order to facilitate a smooth review, approval, and implementation of future clinical research. The Company anticipates initiation of the Phase II study by mid-2013.

"We are pleased with the direction and counsel offered by the experts at the PEI," stated Darrell Panich, RepliCel's VP Clinical Affairs. "Our next step is to reappear before a different panel of experts at the PEI next month to obtain counsel that will assist us in finalizing the clinical design which will allow us to complete our application. We are delighted to be one step closer to the initiation of our Phase II trial."

About RepliCel Life Sciences
The Company has developed RepliCeltm, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCeltm procedure has been developed over the past ten years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.

Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and include that RepliCeltm has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women and that RepliCel will initiate the Phase II study by mid-2013. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials; the inability to meet the proposed timeline for clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statements speak only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2011 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.

RepliCel Completes First Pre-Filing Review with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Process

Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013

VANCOUVER, BC - November 7, 2012 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report on its pre-filing scientific meeting with the German Competent Authority responsible for cellular therapies - the Paul Ehrlich Institute (PEI).

During the latter part of 2012, the Company has been making enhancements to the RepliCeltm procedure to improve the quality, characterization, and shelf-life of its autologous hair cell product which has been named RCH-01. RepliCel's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on its proposed current Good Manufacturing Practice(cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of RepliCel's upcoming Phase II, dose-ranging clinical trial. The PEI experts agreed that the proposed manufacturing process for RCH-01 is acceptable for the conduct of a Phase II study and recommended some additional validation work on the manufacturing process be included in the investigational medicinal product dossier (IMPD) that forms part of the clinical trial application.

The results achieved at this meeting have laid the groundwork for the next pre-filing meeting with PEI experts during which time RepliCel's scientific team will discuss the design and methodology of its Phase II clinical trial to be implemented in Germany. This trial is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants. In addition to augmenting the Company's information on the safety of injections of RCH-01, the trial will also provide insight into the optimal treatment regimen for hair growth. The meeting with the PEI, and subsequent confirmation of the design of the Phase II clinical trial, will be completed prior to the end of 2012.

RepliCel's scientific team anticipates the non-binding recommendations received at these meetings, in advance of submitting the formal clinical trial application, will help ensure that all regulatory requirements are met in order to facilitate a smooth review, approval, and implementation of future clinical research. The Company anticipates initiation of the Phase II study by mid-2013.

"We are pleased with the direction and counsel offered by the experts at the PEI," stated Darrell Panich, RepliCel's VP Clinical Affairs. "Our next step is to reappear before a different panel of experts at the PEI next month to obtain counsel that will assist us in finalizing the clinical design which will allow us to complete our application. We are delighted to be one step closer to the initiation of our Phase II trial."

About RepliCel Life Sciences
The Company has developed RepliCeltm, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCeltm procedure has been developed over the past ten years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.

RepliCel Completes First Pre-Filing Review with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Process

Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013

VANCOUVER, BC - November 7, 2012 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report on its pre-filing scientific meeting with the German Competent Authority responsible for cellular therapies - the Paul Ehrlich Institute (PEI).

During the latter part of 2012, the Company has been making enhancements to the RepliCeltm procedure to improve the quality, characterization, and shelf-life of its autologous hair cell product which has been named RCH-01. RepliCel's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on its proposed current Good Manufacturing Practice(cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of RepliCel's upcoming Phase II, dose-ranging clinical trial. The PEI experts agreed that the proposed manufacturing process for RCH-01 is acceptable for the conduct of a Phase II study and recommended some additional validation work on the manufacturing process be included in the investigational medicinal product dossier (IMPD) that forms part of the clinical trial application.

The results achieved at this meeting have laid the groundwork for the next pre-filing meeting with PEI experts during which time RepliCel's scientific team will discuss the design and methodology of its Phase II clinical trial to be implemented in Germany. This trial is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants. In addition to augmenting the Company's information on the safety of injections of RCH-01, the trial will also provide insight into the optimal treatment regimen for hair growth. The meeting with the PEI, and subsequent confirmation of the design of the Phase II clinical trial, will be completed prior to the end of 2012.

RepliCel's scientific team anticipates the non-binding recommendations received at these meetings, in advance of submitting the formal clinical trial application, will help ensure that all regulatory requirements are met in order to facilitate a smooth review, approval, and implementation of future clinical research. The Company anticipates initiation of the Phase II study by mid-2013.

"We are pleased with the direction and counsel offered by the experts at the PEI," stated Darrell Panich, RepliCel's VP Clinical Affairs. "Our next step is to reappear before a different panel of experts at the PEI next month to obtain counsel that will assist us in finalizing the clinical design which will allow us to complete our application. We are delighted to be one step closer to the initiation of our Phase II trial."

About RepliCel Life Sciences
The Company has developed RepliCeltm, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCeltm procedure has been developed over the past ten years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.

VANCOUVER, BC - November 7, 2012 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report on its pre-filing scientific meeting with the German Competent Authority responsible for cellular therapies - the Paul Ehrlich Institute (PEI).

During the latter part of 2012, the Company has been making enhancements to the RepliCeltm procedure to improve the quality, characterization, and shelf-life of its autologous hair cell product which has been named RCH-01. RepliCel's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on its proposed current Good Manufacturing Practice(cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of RepliCel's upcoming Phase II, dose-ranging clinical trial. The PEI experts agreed that the proposed manufacturing process for RCH-01 is acceptable for the conduct of a Phase II study and recommended some additional validation work on the manufacturing process be included in the investigational medicinal product dossier (IMPD) that forms part of the clinical trial application.

The results achieved at this meeting have laid the groundwork for the next pre-filing meeting with PEI experts during which time RepliCel's scientific team will discuss the design and methodology of its Phase II clinical trial to be implemented in Germany. This trial is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants. In addition to augmenting the Company's information on the safety of injections of RCH-01, the trial will also provide insight into the optimal treatment regimen for hair growth. The meeting with the PEI, and subsequent confirmation of the design of the Phase II clinical trial, will be completed prior to the end of 2012.

RepliCel's scientific team anticipates the non-binding recommendations received at these meetings, in advance of submitting the formal clinical trial application, will help ensure that all regulatory requirements are met in order to facilitate a smooth review, approval, and implementation of future clinical research. The Company anticipates initiation of the Phase II study by mid-2013.

"We are pleased with the direction and counsel offered by the experts at the PEI," stated Darrell Panich, RepliCel's VP Clinical Affairs. "Our next step is to reappear before a different panel of experts at the PEI next month to obtain counsel that will assist us in finalizing the clinical design which will allow us to complete our application. We are delighted to be one step closer to the initiation of our Phase II trial."

About RepliCel Life Sciences
The Company has developed RepliCeltm, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCeltm procedure has been developed over the past ten years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.

Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and include that RepliCeltm has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women and that RepliCel will initiate the Phase II study by mid-2013. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials; the inability to meet the proposed timeline for clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statements speak only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2011 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.

RepliCel Completes First Pre-Filing Review with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Process

Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013

VANCOUVER, BC - November 7, 2012 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report on its pre-filing scientific meeting with the German Competent Authority responsible for cellular therapies - the Paul Ehrlich Institute (PEI).

During the latter part of 2012, the Company has been making enhancements to the RepliCeltm procedure to improve the quality, characterization, and shelf-life of its autologous hair cell product which has been named RCH-01. RepliCel's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on its proposed current Good Manufacturing Practice(cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of RepliCel's upcoming Phase II, dose-ranging clinical trial. The PEI experts agreed that the proposed manufacturing process for RCH-01 is acceptable for the conduct of a Phase II study and recommended some additional validation work on the manufacturing process be included in the investigational medicinal product dossier (IMPD) that forms part of the clinical trial application.

The results achieved at this meeting have laid the groundwork for the next pre-filing meeting with PEI experts during which time RepliCel's scientific team will discuss the design and methodology of its Phase II clinical trial to be implemented in Germany. This trial is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants. In addition to augmenting the Company's information on the safety of injections of RCH-01, the trial will also provide insight into the optimal treatment regimen for hair growth. The meeting with the PEI, and subsequent confirmation of the design of the Phase II clinical trial, will be completed prior to the end of 2012.

RepliCel's scientific team anticipates the non-binding recommendations received at these meetings, in advance of submitting the formal clinical trial application, will help ensure that all regulatory requirements are met in order to facilitate a smooth review, approval, and implementation of future clinical research. The Company anticipates initiation of the Phase II study by mid-2013.

"We are pleased with the direction and counsel offered by the experts at the PEI," stated Darrell Panich, RepliCel's VP Clinical Affairs. "Our next step is to reappear before a different panel of experts at the PEI next month to obtain counsel that will assist us in finalizing the clinical design which will allow us to complete our application. We are delighted to be one step closer to the initiation of our Phase II trial."

About RepliCel Life Sciences
The Company has developed RepliCeltm, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCeltm procedure has been developed over the past ten years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available atwww.replicel.com.

Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and include that RepliCeltm has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women and that RepliCel will initiate the Phase II study by mid-2013. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials; the inability to meet the proposed timeline for clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statements speak only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2011 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.

RepliCel Completes First Pre-Filing Review with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Process

Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013

VANCOUVER, BC - November 7, 2012 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report on its pre-filing scientific meeting with the German Competent Authority responsible for cellular therapies - the Paul Ehrlich Institute (PEI).

During the latter part of 2012, the Company has been making enhancements to the RepliCeltm procedure to improve the quality, characterization, and shelf-life of its autologous hair cell product which has been named RCH-01. RepliCel's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on its proposed current Good Manufacturing Practice(cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of RepliCel's upcoming Phase II, dose-ranging clinical trial. The PEI experts agreed that the proposed manufacturing process for RCH-01 is acceptable for the conduct of a Phase II study and recommended some additional validation work on the manufacturing process be included in the investigational medicinal product dossier (IMPD) that forms part of the clinical trial application.

The results achieved at this meeting have laid the groundwork for the next pre-filing meeting with PEI experts during which time RepliCel's scientific team will discuss the design and methodology of its Phase II clinical trial to be implemented in Germany. This trial is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants. In addition to augmenting the Company's information on the safety of injections of RCH-01, the trial will also provide insight into the optimal treatment regimen for hair growth. The meeting with the PEI, and subsequent confirmation of the design of the Phase II clinical trial, will be completed prior to the end of 2012.

RepliCel's scientific team anticipates the non-binding recommendations received at these meetings, in advance of submitting the formal clinical trial application, will help ensure that all regulatory requirements are met in order to facilitate a smooth review, approval, and implementation of future clinical research. The Company anticipates initiation of the Phase II study by mid-2013.

"We are pleased with the direction and counsel offered by the experts at the PEI," stated Darrell Panich, RepliCel's VP Clinical Affairs. "Our next step is to reappear before a different panel of experts at the PEI next month to obtain counsel that will assist us in finalizing the clinical design which will allow us to complete our application. We are delighted to be one step closer to the initiation of our Phase II trial."

About RepliCel Life Sciences
The Company has developed RepliCeltm, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCeltm procedure has been developed over the past ten years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.

Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and include that RepliCeltm has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women and that RepliCel will initiate the Phase II study by mid-2013. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials; the inability to meet the proposed timeline for clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statements speak only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2011 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.

Replicel Update Today

http://www.stockhouse.com/news...sdetail.aspx?n=8661951

FYI Their Canadian patent is still pending. I wouldn't hold my breath with these guys. How long have you been hearing "should be ready for public in 3-5 years" Once those years are over, the companies stop getting funding and the "researchers" are on to the next project for funding.

P.S I've seen youtube videos of this company that were posted Nov 2011. They've got a total whopping 4,000 views with 4 comments per. Clearly they guys are breaking bounds when it comes to something big.

VANCOUVER, BC - February 4, 2013 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report that it will be meeting with the German Competent Authority responsible for cellular therapies (the Paul Ehrlich Institute (PEI)) to discuss plans for its upcoming Phase II clinical trial for its autologous hair cell product, RCH-01, on February 5, 2013.

In November, RepliCel's scientific team had its first meeting with experts from the PEI to discuss important improvements to its current Good Manufacturing Practice (cGMP)-compliant manufacturing process for RCH-01. Tomorrow's meeting will address updates made to the manufacturing process that were recommended at the last PEI meeting, as well as plans the Company has to conduct a Phase II clinical trial in Germany. This study is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants. In addition to augmenting the Company's information on the safety of injections of RCH-01, the trial will also provide insight into the optimal treatment regimen to increase hair growth.

"We are happy with the progress made with the design of our upcoming Phase II trial and are quite eager to get input from the PEI that will allow us to conduct the best clinical trial for the development of our product," stated Darrell Panich, Vice-President of Clinical Affairs. "Designing a trial in consultation with the PEI will facilitate the completion of the formal clinical trial application for our upcoming trial." The Company anticipates initiation of the Phase II study this year.

"The Company has made significant advancements in its manufacturing procedures and these improvements are expected to have a meaningful impact on our RCH-01 program," commented David Hall, CEO. "We are committed to receiving guidance and implementing the recommendations provided by the regulatory authorities to ensure we have a well-constructed Phase II trial that will lead to the optimum dose to treat pattern baldness. Our proposed Phase II dosing trial will provide us with 288 data points as compared to 16 in our Phase I safety trial. This should allow us to isolate an effective treatment regime," concluded Mr. Hall.

RepliCel to Present at the 11th Annual BioPartnering
North America Conference

Vancouver Convention Centre, Vancouver, BC, February 24-26th, 2013

VANCOUVER, BC - February 19th 2013 - RepliCel Life Sciences Inc (the "Company" or "RepliCel") (OTCBB: REPCF) (CNSX: RP) today announced that the Company will present to a select group of biotech industry investors and experts at the 11th Annual BioPartnering North America Conference ("BPN") in Vancouver, BC, on Monday, February 25th at 10:30am in room 121. David Hall, CEO, will give a corporate overview on RepliCel's autologous cell replication technology and current clinical development plans.

Following the BPN conference, RepliCel is set to attend the 7th World Congress for Hair Research in Edinburgh on May 4-6th 2013. The Company looks forward to another international gathering of the global hair research societies.

About BioPartnering North America
BPN, the only global life science conference in Canada, provides presenters, exhibitors, and attendees with a unique chance to access innovations and technologies from all around the world. By bringing together senior executives from venture capital firms, major pharmaceutical companies, academia, and government representatives, BPN offers networking and information sharing opportunities. RepliCel's presentation will be made available on the Company's web site. This year, the 3-day event starts on February 24th. To learn more about the conference, visit their web site at www.techvision.com/bpn/.

About RepliCel Life Sciences
The Company has developed RepliCeltm, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. RepliCeltm is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCeltm procedure has been developed over the past ten years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at www.replicel.com.

For more information please contact:
Tammey George, Director of Communications
Telephone: 604-248-8696
tg@replicel.com
www.replicel.com

https://mail.google.com/mail/ca/u/0/#inbox/13e6bae43a8019b6

Latest Replicel Press Release